title: Eltrombopag: How secure in triple therapy of HCV?
abstract: Triple therapy of hepatitis C usually leads to some hematological and dermatological side effects. Thrombocytopenia is one of the most common side effects that are encountered during triple therapy. Eltrombopag was approved for the treatment of patients with chronic hepatitis C and thrombocytopenia to allow the initiation and maintenance of interferon based therapies. During eltrombopag therapy, some side effects like headache, abdominal pain, and some complications such as portal vein thrombosis, deep vein thrombosis and arterial thrombosis were observed more frequently than placebo. We described here a patient who developing thrombosis secondary to eltrombopag in receiving triple therapy.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Kayar
authors.forename: Ahmet
authors.initials: A
authors.lastname: Danalioglu
authors.forename: Orhan
authors.initials: O
authors.lastname: Kocaman
authors.forename: Birol
authors.initials: B
authors.lastname: Baysal
authors.forename: Hakan
authors.initials: H
authors.lastname: Senturk
mesh_terms: D001565:Benzoates / Q000009:adverse effects*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects*; D008875:Middle Aged; D011720:Pyrazoles / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced*
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; C520809:eltrombopag